Nuveen
ANTX icon

Nuveen’s AN2 Therapeutics ANTX Stock Holding History

Nuveen’s Portfolio ANTX Stock Details ANTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$171K Buy
+35,333
New +$152K ﹤0.01% 3664
2023
Q2 		– Sell
-15,546
Closed -$153K – 3210
2023
Q1 		$153K Buy
15,546
+481
+3% +$5.35K ﹤0.01% 3020
2022
Q4 		$144K Buy
+15,065
New +$202K ﹤0.01% 3077

Other funds holding ANTX

VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSC
Spruce Street Capital New York $510M AUM
AC
Almitas Capital Santa Monica, California $417M AUM 22.81% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
BCM
Boxer Capital Management San Diego, California $1.33B AUM 864.5% 1-Year Est. Return

Nuveen's ANTX Position: Q2 2026 in Review

Nuveen opened a new position in AN2 Therapeutics (ANTX) in Q2 2026: 35,333 shares worth $171K. The stake represents ﹤0.01% of the portfolio and ranks #3664 among its holdings. This is a return to the name: Nuveen previously reported a position in ANTX as recently as Q1 2023.

Nuveen first reported a position in ANTX in Q4 2022 and has held it in 3 quarters since. 66 funds tracked by Wall St. Rank hold ANTX as of Q2 2026.

  • Nuveen held 35,333 shares of AN2 Therapeutics worth $171K as of Q2 2026.
  • AN2 Therapeutics was a new Nuveen position in Q2 2026.
  • AN2 Therapeutics made up ﹤0.01% of Nuveen's portfolio in Q2 2026, its #3664 holding.
  • Nuveen first reported a position in AN2 Therapeutics in Q4 2022 and has held it in 3 quarters since.
  • 66 funds tracked by Wall St. Rank held AN2 Therapeutics as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.